Iterum Therapeutics, International Limited

Open enrollment with a later-stage pipeline tilt

According to ClinicalTrials.gov-derived indexes, Iterum Therapeutics, International Limited sits in the upper quartile of US sponsors by registered trial count (#2,085 of 15,742 sponsors by registered trial count).

6 total trials 1 currently recruiting 5 completed later-stage tilt upper quartile by trial count

Iterum Therapeutics, International Limited: 6 sponsored US clinical trials, 1 recruiting.

Iterum Therapeutics, International Limited sponsors 6 registered US clinical trials on ClinicalTrials.gov, 1 of them currently recruiting, and 5 completed. 5 of these trials are in Phase 3-4 (later-stage) and 1 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Complicated Urinary Tract Infections, with 1 trials.

Upper-quartile sponsor footprint

Iterum Therapeutics, International Limited sits in the upper quartile of the sponsor corpus (#2,085 of 15,742 sponsors by registered trial count) - denser than most sponsors, still short of the top-decile hubs.

Open and recent trials

6 total, page 1 of 1

RECRUITING Phase 1

Pharmacokinetics of Sulopenem Etzadroxil Plus Probenecid in Adolescents

NCT07092813
COMPLETED Phase 3

Oral Sulopenem Versus Amoxicillin/Clavulanate for Uncomplicated Urinary Tract Infection in Adult Women

NCT05584657
COMPLETED Phase 3

Sulopenem Followed by Sulopenem-etzadroxil/Probenecid vs Ertapenem Followed by Cipro for Complicated UTI in Adults

NCT03357614
COMPLETED Phase 3

Sulopenem Versus Ertapenem for Complicated Intra-abdominal Infection (cIAI)

NCT03358576
COMPLETED Phase 3

Oral Sulopenem-etzadroxil/Probenecid Versus Ciprofloxacin for Uncomplicated Urinary Tract Infection in Adult Women

NCT03354598
COMPLETED Phase 4

Efficacy of Ciprofloxacin for the Treatment of Uncomplicated Urinary Tract Infection (uUTI)

NCT03366207

Phase Distribution

PhaseTrial count
Phase 1 1
Phase 3 4
Phase 4 1

Therapeutic Areas

Complicated Urinary Tract Infections 1
Uncomplicated Urinary Tract Infections 1
Cystitis 1
Pharmacokinetics After Oral Intake 1
Urinary Tract Infections 1

Where Iterum Therapeutics, International Limited enrollment is open (later-stage tilt)

1 recruiting of 6 indexed (17% open); 5 completed (83%).

Phase mix: 5 late (III/IV) vs 1 early (I/II) (later-stage heavy).

Top condition: Complicated Urinary Tract Infections (1 trial), 4 others listed.

How open-pipeline share is computed

Recruiting share is recruiting_count divided by trial_count for this sponsor in the public registry export. Status can change between pulls; treat the figure as a research-attention snapshot, not product availability.

Iterum Therapeutics, International Limited: open-pipeline peers nationwide

Peers matched on 6 registered trials and 17% open enrollment, not the therapeutic-area sidebar.

Iterum Therapeutics, International Limited sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together. Source: ClinicalTrials.gov (2026-08-08 snapshot). 2×2 strategic matrix plotting 9 entities by Total trials (X) and Recruiting share (Y), with a crosshair dividing the plot into four quadrants. Higher volume & more openFocused & more openHigher volume, mostly closedSmaller & mostly closed 468101214 0%20%40%60%80% Total trials Recruiting share Iterum Therapeutics, International Limited23andMeAardvark TherapeuticsAbbisko Therapeutics CoAbGenomics B.V Taiwan BranchAdageneAgendiaAkamis BioAngiodynamics
Iterum Therapeutics, International Limited sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together. Source: ClinicalTrials.gov (2026-08-08 snapshot).

Iterum Therapeutics, International Limited sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.

Sponsors near 6 trials (± recruiting share)

Sponsors near 17% open enrollment (± trial volume)

Related

Read our methodology - how this data is sourced, computed, and verified.

What to do with this Iterum Therapeutics, International Limited page

6 registered trials is a research-attention snapshot, not an endorsement of Iterum Therapeutics, International Limited or any single study.

  • 1 of Iterum Therapeutics, International Limited's trials are currently recruiting, check each one's own eligibility criteria before contacting a site. Browse recruiting trials
  • Complicated Urinary Tract Infections is the condition Iterum Therapeutics, International Limited studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Complicated Urinary Tract Infections trials
  • Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide

Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. Iterum Therapeutics, International Limited pipeline card: 6 registered trials from official public datasets. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.